{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:47:30Z","timestamp":1740134850443,"version":"3.37.3"},"reference-count":9,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"DOI":"10.1182\/blood.2023022494","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:31:50Z","timestamp":1706805110000},"page":"382-383","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["How do you define treatment success in MZL?"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-9932","authenticated-orcid":false,"given":"Carla","family":"Casulo","sequence":"first","affiliation":[{"name":"University of Rochester"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"5","key":"2024020116313900700_bib1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood.2023020984","article-title":"Early complete response as validated surrogate marker in extranodal marginal zone lymphoma\u00a0systemic therapy","volume":"143","author":"Bommier","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2024020116313900700_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they\u00a0currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"issue":"6","key":"2024020116313900700_bib3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.mayocp.2016.02.012","article-title":"Strength of validation for surrogate end points used in the US Food and Drug Administration's approval of oncology drugs","volume":"91","author":"Kim","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"2024020116313900700_bib4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024020116313900700_bib5","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3324\/haematol.2019.237990","article-title":"Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment","volume":"105","author":"Conconi","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"2024020116313900700_bib6","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.2019001088","article-title":"Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study","volume":"134","author":"Luminari","year":"2019","journal-title":"Blood"},{"issue":"17","key":"2024020116313900700_bib7","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024020116313900700_bib8","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1007\/s00259-022-05683-2","article-title":"Clinical and pathological predictors for FDGPET\/CT avidity in patients with marginal zone lymphoma-a retrospective cohort study","volume":"49","author":"Kagan","year":"2022","journal-title":"Eur\u00a0J\u00a0Nucl Med Mol Imaging"},{"issue":"2","key":"2024020116313900700_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hon.2578","article-title":"FDG PET\/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma","volume":"37","author":"Vaxman","year":"2019","journal-title":"Hematol Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/5\/382\/2210907\/blood_bld-2023-022494-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/5\/382\/2210907\/blood_bld-2023-022494-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:31:57Z","timestamp":1706805117000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/5\/382\/514730\/How-do-you-define-treatment-success-in-MZL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022494","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}